home / openregs / dockets

dockets: FDA-2007-P-0188

Regulatory dockets from Regulations.gov — containers for related documents and comments in a rulemaking proceeding.

Data license: Public Domain (U.S. Government data) · Data source: U.S. government sources, plus a few identifier registries; each is listed on the methodology page

This data as json

id agency_id title docket_type last_modified object_id rin dkabstract category subtype keywords program short_title effective_date organization attrs_raw attr_source
FDA-2007-P-0188 FDA Determine Whether a Food-Effect Study Should be Required as Part of the Demonstration of Bioequivalence for Clozapine Orally Disintegrating Tablets (ODT), 100 mg Nonrulemaking 2021-09-01T01:01:02Z 0b0000648042a75c   Docket Status: CLOSED per Petition Denial Letter dtd 5/6/2015     ["orally", "fazaClo", "100 mg", "odt", "disintegrating tablets", "clozapine", "bioequivalence", "food-effect", "CDER", "closed"] CDER Determine whether a food-effect study should be required as part of the demonstration of bioequivalence for clozapine orally disintegrating tablets (ODT), 100 mg     {"displayProperties": [{"name": "abstract", "label": "General Information", "tooltip": "Describes an agency's specific regulatory action; equivalents: Abstract, Description, Docket Subject, Related To, Summary."}, {"name": "legacyId", "label": "Legacy ID", "tooltip": "A pre-FDMS agency specific identifier migrated from a legacy system."}, {"name": "generic", "label": "Docket Item Code", "tooltip": "An agency specific code that identifies the type of document that established the docket (regulatory action)."}, {"name": "program", "label": "Center", "tooltip": "The agency specific program associated with the docket (regulatory action); equivalents: Docket Item Code, Location."}, {"name": "field2", "label": "Docket Status", "tooltip": "Used to Identity that a Docket's Status is Open or Closed"}, {"name": "shortTitle", "label": "Short Title", "tooltip": "A combination of letters and or numbers assigned to an agency's regulatory action for purposes of brevity."}], "keywords": ["orally", "fazaClo", "100 mg", "odt", "disintegrating tablets", "clozapine", "bioequivalence", "food-effect", "CDER", "closed"], "modifyDate": "2021-09-01T01:01:02Z", "dkAbstract": "Docket Status: CLOSED per Petition Denial Letter dtd 5/6/2015", "agencyId": "FDA", "program": "CDER", "shortTitle": "Determine whether a food-effect study should be required as part of the demonstration of bioequivalence for clozapine orally disintegrating tablets (ODT), 100 mg", "subType2": null, "title": "Determine Whether a Food-Effect Study Should be Required as Part of the Demonstration of Bioequivalence for Clozapine Orally Disintegrating Tablets (ODT), 100 mg", "generic": "P", "field1": null, "docketType": "Nonrulemaking", "petitionNbr": null, "rin": null, "organization": null, "legacyId": "2007P-0499", "subType": null, "category": null, "field2": "CLOSED", "effectiveDate": null, "objectId": "0b0000648042a75c"} single_get

Links from other tables

  • 6 rows from docket_id in documents
Powered by Datasette · Queries took 0.219ms · Data license: Public Domain (U.S. Government data) · Data source: U.S. government sources, plus a few identifier registries; each is listed on the methodology page · Privacy